Pharmaceuticals
Warburg Pincus leads Series B for China's Haihe Pharmaceutical
Warburg Pincus has led a RMB1.2 billion ($171 million) Series B round for Haihe Pharmaceutical, a Chinese cancer drug developer that currently has four treatments in stage-three clinical trials or beyond.
China biotech player Antengene raises $97m Series C
Fidelity Investments has led a $97 million Series C round for Chinese hematology and oncology biotech developer Antengene.
PE-backed Junshi Biosciences shines on Star Market debut
PE-backed Junshi Biosciences has become the first Chinese biotech company to list in Hong Kong and the mainland, following a strong debut on Shanghai's Star Market.
Chinese biotech company Arctic Vision raises $32m
China-based ophthalmology therapy provider Arctic Vision has raised a $32 million Series A round led by Morningside Ventures.
Quan leads $80m Series A for China biotech player
Healthcare-focused VC firm Quan Capital has led an $80 million Series A round for Citrine Medicine, a Chinese biotech developer set up by Eight Roads, F-Prime Capital, and Vivo Capital.
Portfolio: CBC Group and I-Mab Biopharma
CBC Group’s stewardship of I-Mab Biopharma brings an intensely hands-on platform-based approach to a booming China biotech space often characterized by relatively passive strategies
China’s Harbour BioMed raises $103m Series C
Chinese biotech start-up Harbour BioMed has raised $102.8 million in Series C funding. It comes four months after it closed an extended Series B round of $75 million.
China's Gan & Lee Pharmaceuticals gains after A-share debut
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR to buy control of Indian pharma player
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.
China healthcare IPOs: Good prognosis?
There has been a steady stream of China healthcare IPOs - most of them drug developers - on the domestic, Hong Kong and US bourses in recent months. They might be benefiting from a COVID-19 tailwind but it won't be permanent
Carlyle to buy 20% of Piramal's India pharma business
The Carlyle Group has agreed to invest approximately $490 million for a 20% stake in pharmaceutical division of India’s Piramal Enterprises, which has interests ranging from outsourced drug development to an ophthalmology joint venture with Allergan.
General Atlantic invests $100m in Chinese drug maker
General Atlantic has invested $100 million in NASDAQ-listed Chinese cancer drug developer Hutchison China MediTech - also known as Chi-Med - a subsidiary of Hong Kong conglomerate CK Hutchison Holdings.
VC-backed SinocellTech enjoys strong Star Market debut
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
China's Miaoshou Doctor raises $85m
Miaoshou Doctor, a Chinese online healthcare services platform, has raised RMB600 million ($85 million) in the first tranche of Series D funding round backed by the likes of Qiming Venture Partners, Sequoia Capital China, Ince Capital Partners, CITIC...
CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
Chinese drug developer Everest secures $310m Series C
Everest Medicines, a China-based biopharmaceutical company, has raised $310 million in Series C funding across two tranches.
Deal focus: IMM overcomes distancing disruption
Health and safety was a priority when IMM Private Equity negotiated a $413 million carve-out of Korea Kolmar Holdings' drug outsourcing business against the backdrop of COVID-19
Hillhouse leads $160m Series B for China's Genor Biopharma
Genor Biopharma, a Shanghai-based innovative drug developer, has raised $160 million in Series B funding led by Hillhouse Capital.
Shiyu leads $276m round for China's Mabwell Biotech
Mabwell Biotech, a Chinese drug developer with one treatment cleared for production, has raised RMB1.97 billion ($276 million) in Series A funding across two tranches led by specialist healthcare investor Shiyu Capital.
Sequoia leads $30m round for China's Atom Bioscience
Chinese drug developer Jiangsu Atom Bioscience & Pharmaceutical has raised $30 million in Series B funding led by Sequoia Capital China and Hong Kong-listed Livzon Pharmaceutical Group.
IMM agrees $413m Korea pharma acquisition
IMM Private Equity has agreed to acquire Korea Kolmar Holdings’ pharmaceutical contract development and manufacturing organization (CDMO) for KRW512.5 billion ($413 million).
PE-backed Kintor Pharma raises $240m in Hong Kong IPO
Kintor Pharmaceutical, a Chinese drug developer backed by the likes of HighLight Capital and Shenzhen Green Pine Capital Partners, posted a 7% gain on debut following a HK$1.86 billion ($240 million) Hong Kong IPO.
Zentalis raises $20m for China drug development venture
Zentalis Pharmaceuticals, a US cancer treatment specialist that raised $165 million in an IPO last month, has secured $20 million in funding to establish a China-based joint venture.
Optum, Health Catalyst back Singapore's Holmusk
US investors Optum Ventures and Health Catalyst Capital have co-led a $21.5 million Series A round for Singapore-based healthcare technology developer Holmusk.